Figure 1 (Figure 1)
Lokelma Powder, For Suspension
Product Images NDC 50090-6501
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lokelma (NDC 50090-6501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure_2 (Figure 2)
The text lists various medications and their dosages including Lokelma, amlodipine, atorvastatin, clopidogrel, dabigatran, furosemide, glipizide, levothyroxine, triodothyronine, losartan, tacrolimus, and cyclosporin. The abbreviation "AUC" appears multiple times followed by "Cmax," which may refer to pharmacokinetic parameters. The final line of text contains ratios for the "LOKELMA + co-administered drug" compared to "co-administered drug alone."*
Figure_3 (Figure 3)
The text appears to be a table with serum potassium measurements at different doses for different groups of people. The groups include those taking a placebo and those taking doses of 5g, 10g and 15g of some substance. The table also includes the number of people in each group and their contributions to some primary endpoint. There are also two phases indicated, one an acute phase measured in hours and the other a randomized withdrawal phase measured in days. There are some missing values indicated with a plus sign. It is not clear what the substance being studied or the endpoint being measured are.*
Figure 4 (Figure 4)
Figure_5 (Image 01)
Label Image (Lbl500906501)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
